Blog

Updated label for Daklinza (daclatasvir) for the 12-week treatment of non-cirrhotic patients with chronic hepatitis C genotype 3 approved by the European Commission

10 September 2015 - Bristol-Myers Squibb Company announced today that the European Commission has approved an updated label for Daklinza for ...